The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.
This grant focuses on accelerating the translation of NCI-supported assays to clinical application, specifically for cancer detection, diagnosis, prognosis, monitoring, treatment response prediction, and cancer control and prevention. It aims to adapt and clinically validate molecular, cellular, and imaging markers ("biomarkers"). Eligibility is limited to active NIH R01 recipients seeking to revise their projects for the clinical validation of these assays. Successful proposals will demonstrate a multi-disciplinary approach, involving collaboration among scientists, clinicians, statisticians, and clinical laboratory staff. The grant does not support early-stage technology development or clinical trial conduct but rather the adaptation and validation of assays for potential integration into clinical trials as investigational tools.